FGF-23 is a biomarker of RV dysfunction and congestion in patients with HFrEF.

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378050%3A_____%2F23%3A00579894" target="_blank" >RIV/68378050:_____/23:00579894 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00023001:_____/23:00084199 RIV/00216208:11110/23:10469113 RIV/00216208:11120/23:43926047

Výsledek na webu

<a href="https://www.nature.com/articles/s41598-023-42558-4" target="_blank" >https://www.nature.com/articles/s41598-023-42558-4</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41598-023-42558-4" target="_blank" >10.1038/s41598-023-42558-4</a>

Jazyk výsledku

angličtina

Název v původním jazyce

FGF-23 is a biomarker of RV dysfunction and congestion in patients with HFrEF.

Popis výsledku v původním jazyce

There is no biomarker reflecting right ventricular dysfunction in HFrEF patients used in clinical practice. We have aimed to look for a circulating marker of RV dysfunction employing a quantitative proteomic strategy. The Olink Proteomics Multiplex panels (Cardiovascular Disease II, III, Cardiometabolic, and Inflammation Target Panels) identified FGF-23 to be the most differentially abundant (more than 2.5-fold) in blood plasma of HF patients with severe RV dysfunction (n=30) compared to those with preserved RV function (n=31). A subsequent ELISA-based confirmatory analysis of circulating FGF-23 in a large cohort of patients (n=344, 72.7% NYHA III/IV, LVEF 22.5%, 54.1% with moderate/severe RV dysfunction), followed by multivariable regression analysis, revealed that the plasma FGF-23 level was most significantly associated with RV dysfunction grade (p=0.0004) and congestion in the systemic circulation (p=0.03), but not with LV-ejection fraction (p=0.69) or estimated glomerular filtration rate (eGFR, p=0.08). FGF-23 was associated with the degree of RV dysfunction in both sub-cohorts (i.e. in patients with and without congestion, p<0.0001). The association between FGF-23 and RV-dysfunction remained significant after the adjustment for BNP (p=0.01). In contrast, when adjusted for BNP, FGF-23 was no longer associated with LV dysfunction (p=0.59). The Cox proportional hazard model revealed that circulating FGF-23 was significantly associated with adverse outcomes even after adjusting for BNP, LVEF, RV dysfunction grade and eGFR. Circulating FGF-23 isthus a biomarker of right ventricular dysfunction in HFrEF patients regardless of congestion status.

Název v anglickém jazyce

FGF-23 is a biomarker of RV dysfunction and congestion in patients with HFrEF.

Popis výsledku anglicky

There is no biomarker reflecting right ventricular dysfunction in HFrEF patients used in clinical practice. We have aimed to look for a circulating marker of RV dysfunction employing a quantitative proteomic strategy. The Olink Proteomics Multiplex panels (Cardiovascular Disease II, III, Cardiometabolic, and Inflammation Target Panels) identified FGF-23 to be the most differentially abundant (more than 2.5-fold) in blood plasma of HF patients with severe RV dysfunction (n=30) compared to those with preserved RV function (n=31). A subsequent ELISA-based confirmatory analysis of circulating FGF-23 in a large cohort of patients (n=344, 72.7% NYHA III/IV, LVEF 22.5%, 54.1% with moderate/severe RV dysfunction), followed by multivariable regression analysis, revealed that the plasma FGF-23 level was most significantly associated with RV dysfunction grade (p=0.0004) and congestion in the systemic circulation (p=0.03), but not with LV-ejection fraction (p=0.69) or estimated glomerular filtration rate (eGFR, p=0.08). FGF-23 was associated with the degree of RV dysfunction in both sub-cohorts (i.e. in patients with and without congestion, p<0.0001). The association between FGF-23 and RV-dysfunction remained significant after the adjustment for BNP (p=0.01). In contrast, when adjusted for BNP, FGF-23 was no longer associated with LV dysfunction (p=0.59). The Cox proportional hazard model revealed that circulating FGF-23 was significantly associated with adverse outcomes even after adjusting for BNP, LVEF, RV dysfunction grade and eGFR. Circulating FGF-23 isthus a biomarker of right ventricular dysfunction in HFrEF patients regardless of congestion status.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10608 - Biochemistry and molecular biology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Scientific Reports

ISSN

2045-2322

e-ISSN

2045-2322

Svazek periodika

13

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

9

Strana od-do

16004

Kód UT WoS článku

001116558400022

EID výsledku v databázi Scopus

2-s2.0-85172334413